[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anal-squamous-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anal-squamous-cell-carcinoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,60,83,105,133,157,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100609637","phase-1-a-study-evaluating-the-safety-efficacy-and-pharmacokinetics-pk-of-evolve104-in-participants-with-advanced-urothelial-and-squamous-cell-carcinomas-100609637",false,"NCT07217171","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas","Key Inclusion Criteria:\n\nParticipants must have locally advanced or metastatic cancer with one of the following tumor types: bladder cancer, squamous cell carcinoma of the lung, esophagus, skin, or an anogenital squamous cell carcinoma.\n\n1. Participant must have documented disease progression during or post treatment with standard of care, dependent upon tumor type.\n2. The cancer must be measurable by CT scan or MRI.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤1.\n4. Anticipated life expectancy of at least 3 months.\n5. Adequate organ function, as indicated by standard blood tests.\n6. Able to provide a fresh or archival tumor biopsy.\n7. Male and female participants must agree to use contraception during the study and for 120 days after the last dose of study drug, except for women who are post-menopausal or surgically sterile.\n\nKey Exclusion Criteria:\n\n1. The participant is a candidate for treatment with a targeted agent known to provide a benefit.\n2. Persistent significant toxicities from prior anticancer therapy.\n3. Brain metastases unless previously treated and stable.\n4. Prior severe or life-threatening immunologic reactions to previous therapies.\n5. Significant medical conditions, including but not limited to:\n\n   * History of clinically significant cardiac disease\n   * Severe esophageal disease such as esophageal rupture or severe erosive esophagitis.\n   * Active inflammatory corneal or conjunctival inflammation, erosion, or ulcerations.\n   * History of cirrhosis or significant portal hypertension.\n   * Uncontrolled or significant infection.\n   * History of certain other cancers in the past 3 years.\n   * History of arterial thrombosis, stroke and transient ischemic attack within 6 months.\n   * Active or uncontrolled HIV, HBV or HCV infection.\n   * Autoimmune or other condition requiring chronic systemic immunosuppression.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.",[26,27,28,29,30,31,32,33,34,35,36],"Bladder Cancer","Squamous Cell Carcinoma of the Lung","Esophageal Squamous Cell Carcinoma","Tongue Squamous Cell Carcinoma","Cutaneous Squamous Cell Cancer","Penile Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","Vulvar Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Vaginal Squamous Cell Carcinoma","Urethral Squamous Cell Carcinoma",[38,39,40,41,42,43,44,45,46],"bladder","lung","esophagus","tongue","penile","anal","vulvar","cervical","vaginal","RECRUITING","2026-07-01",{"date":50,"type":51},"2026-07-02","ACTUAL",{"date":53,"type":51},"2025-11-13",{"date":55,"type":20},"2031-01-29",{"name":57,"class":58},"EvolveImmune United, Inc","INDUSTRY",12,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100645371","phase-2-phase-2-study-of-pembrolizumab-and-lenvatinib-in-anal-squamous-cell-cancer-100645371","NCT07680088","Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer","A Multicenter Single-arm Phase 2 Study of Pembrolizumab and Lenvatinib in Previously Treated Inoperable or Advanced Anal Squamous Cell Cancer","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of anal squamous cell carcinoma.\n2. The participants should have inoperable local recurrence or advanced cancer (stage 4; any T, any N, M1).\n3. The participants should have received at least one prior line of cytotoxic chemotherapy regimen in palliative setting or have declined cytotoxic chemotherapy use or have a contraindication to receive chemotherapy. Prior use of PD-1 systemic therapy is allowed\n4. ECOG Performance status: 0, 1 or 2.\n5. Adequate organ and bone marrow function as outlined below:\n\n   * Absolute neutrophil count (ANC): ≥1500\u002FµL\n   * Platelets: ≥100 000\u002FµL\n   * Creatinine; creatinine clearance GFR can also be used in place of creatinine or CrCl): Creatinine ≤1.5 × ULN OR Creatinine Clearance ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n   * Total bilirubin: ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n   * aspartate aminotransferase (serum glutamic oxaloacetic transaminase) - AST (SGOT) and ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase) - ALT (SGPT): ≤2.5 × ULN (≤5 × ULN for participants with liver metastases) International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): INR ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n6. A participant will be eligible for inclusion in the study if the participant:\n\n   Female Participants\n\n   • Is not a Women Of Child Bearing Potential (WOCBP): OR\n\n   • Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), as described in Appendix D during the intervention period and for at least 120 days post pembrolizumab or 30 days post lenvatinib, whichever date occurs last. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study intervention.\n   * A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) during screening (for the purpose of confirming eligibility\u002Fenrollment).\n   * Note: If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. (WOCBP should also have a negative pregnancy test within 24 hours before the first dose of study intervention (cycle1 day 1) as described in schedule of Activities Table).\n\n   Male Participants\n\n   Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of lenvatinib:\n   * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR\n   * Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below and in Appendix D:\n\n     * Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.\n     * Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.\n   * Please note that 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only, no male contraception measures are needed.\n7. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n8. Archival tumor tissue sample or fresh core biopsy of a tumor lesion is available. In a situation where a safe and suitable site for a fresh biopsy is not feasible and an archival tissue is not available; patients may still be eligible to enroll after discussing with UTSW PI.\n9. Have adequately controlled BP with or without antihypertensive medications, defined as BP ≤150\u002F90 mm Hg with no change in antihypertensive medications within 1 week before C1D1.\n10. The subject's urinary protein is \\\u003C 1+ on dipstick or routine urinalysis; if urine protein \\> 2+, a 24-hour urine must be collected and must demonstrate \\\u003C 1000 mg of protein in 24 hours to allow participation in the study.\n11. Has a left ventricle ejection fraction \\> 45% as determined by multi-gated acquisition (MUGA) or 2D echocardiogram (ECHO). If patient is asymptomatic and there is a documented MUGA or 2D ECHO completed in the last 18 months, then this will be adequate to confirm eligibility.\n12. Patients receiving therapeutic anticoagulation should be on a stable anticoagulant regimen within 14 days prior to first dose of study drug.\n13. Subjects must have recovered from prior treatment-related toxicities to grade 1 or baseline (Some exception to criterion are, alopecia or clinically stable chronic toxicities that may be requiring ongoing medical management but are not affecting daily function as per investigator assessment, e.g. hypothyroidism or chemotherapy-induced neuropathy etc.).\n14. Participants who have known history of HBV infection are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to C1D1.\n\n    * Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n    * Hepatitis B screening tests are not required unless:\n\n      * Known history of HBV infection\n      * As mandated by local health authority or institution\n15. Participants with known history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\n    * Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n    * Hepatitis C screening tests are not required unless:\n\n      * Known history of HCV infection\n      * As mandated by local health authority or institution\n16. Participants with known history of HIV infection must have well-controlled HIV on anti-retroviral therapy (ART), defined as:\n\n    * Participants on ART must have a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening.\n    * Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.\n    * It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.\n    * Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study.\n    * The combination ART regimen must not contain any antiretroviral medications that interact with CYP3A4 inhibitors\u002Finducers\u002Fsubstrates (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers)\n17. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. Has received chemotherapy within 2 weeks prior to starting study treatment.\n2. Has received any investigational agents for the treatment of the cancer under study within 3 weeks of start of the study.\n3. Has received prior radiotherapy within 3 weeks of start of study intervention or suffers from radiation-related toxicities requiring corticosteroids.\n4. Had a major surgery within 3 weeks prior to first dose of study interventions or has not adequately recovered from a previous major surgery or has ongoing surgical complications, in the opinion of the investigator, that would limit participation in study. Note: Adequate wound healing after major surgery must be assessed clinically by investigator or qualified designee.\n5. Has an uncontrolled intercurrent illness including, but not limited to, ongoing or active bacterial infection requiring systemic antibiotic, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that, in the opinion of the investigator, would limit compliance with study requirements.\n6. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided participants are not on steroid treatment for the CNS metastasis at least 14 days prior to first dose of study intervention. An MRI assessment of the brain may be needed during Screening if clinically indicated as per investigator.\n7. Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula\n8. Has a left ventricle ejection fraction \\\u003C45% as determined by multi-gated acquisition (MUGA) or 2D echocardiogram (ECHO). Among patients with a prior known history of congestive heart failure with a low ejection fraction, then ejection fraction assessment will be performed during screening to determine eligibility.\n9. Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability. Note: Medically controlled arrhythmia would be permitted.\n10. Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation. NOTE: The degree of proximity to major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage\u002Fnecrosis following lenvatinib therapy.\n11. Have prolongation of QTc interval to \\>480 ms.\n12. Has a history of gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator.\n13. Has an active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.\n14. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n15. Has received chronic systemic steroid therapy (exceeding 10 mg daily dose of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n16. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid).\n17. Has a known additional malignancy that is progressing or has required active systemic treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n18. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n19. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Lenvatinib or Pembrolizumab used in study.\n20. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n21. Has a concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n    Note: Hepatitis B and C screening tests are not required unless:\n    * Known history of HBV and HCV infection\n    * As mandated by local health authority or institution\n22. Has had an allogenic tissue\u002Fsolid organ transplant.",{"count":68,"type":20},17,[70],"PHASE2","The goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs. Eligible participants should have also received some form of standard therapy previously for their advanced cancer.\n\nParticipants will be required to come for a clinic visit and infusion of pembrolizumab. Lenvatinib will be taken by mouth at home based on direction provided by physicians and research team.",[32],"NOT_YET_RECRUITING","2026-06-25",{"date":50,"type":51},{"date":77,"type":20},"2026-09-30",{"date":79,"type":20},"2030-09-30",{"name":81,"class":82},"University of Texas Southwestern Medical Center","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100519988","phase-2-mr-adaptive-radiation-therapy-for-anal-cancer-with-escalated-treatment-in-a-risk-optimized-approach-100519988","NCT06050707","MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach","MAESTRO","Inclusion Criteria:\n\n* Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible.\n* Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) \u002F the American Joint Committee on Cancer (AJCC) 8th Ed)\n* Patients must be eligible for definitive RT or CRT\n* Must be ≥ 18 years of age\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer.\n* Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.\n* Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.",{"count":91,"type":20},80,[70],"The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.",[32],"2026-06-09",{"date":97,"type":51},"2026-06-10",{"date":99,"type":51},"2023-09-29",{"date":101,"type":20},"2028-09-01",{"name":103,"class":82},"University Health Network, Toronto",5,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100503679","adaptive-radiation-in-anal-cancer-100503679","NCT05838391","Adaptive Radiation in Anal Cancer","Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically proven, invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal.\n* American Joint Committee on Cancer (AJCC) 8th edition stage T2 \\> 4 cm, T3-4 or N1.\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).\n* Life expectancy of greater than 12 months.\n* Patients must have normal organ and marrow function as defined below:\n* leukocytes greater than or equal to 3,000\u002Fmicroliter\n* absolute neutrophil count greater than or equal to 1,500\u002Fmicroliter\n* platelets greater than or equal to 100,000\u002Fmicroliter\n* total bilirubin within normal institutional limits\n* Aspartate transaminase (AST)(SGOT)\u002FAlanine transaminase (ALT)(SGPT) ≤ 2.5 × institutional upper limit of normal\n* creatinine within normal institutional limits OR creatinine clearance ≥60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal.\n* Females of childbearing potential and males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of study therapy. All pregnancies must be reported.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior or co-existing invasive malignancy (except non-melanomatous skin cancer) unless disease free ≥ 2 years.\n* Prior chemotherapy or radiation for anal cancer.\n* Patients who have undergone complete surgical resection.\n* Presence of recurrent\u002Fmetastatic disease.\n* Prior allergic reaction to 5-Fluorouracil or mitomycin C.\n* Artificial organ prosthetics, pacemakers or other implantable devices.\n* Prior radiotherapy to the pelvis that would result in overlap of radiation therapy fields.\n* Uncontrolled inter-current illness including but not limited to known history of HIV with cluster of differentiation 4 (CD4) count less than 200 or symptomatic cardiac disease.\n* Women who are pregnant or lactating.",{"count":113,"type":20},20,[115],"NA","This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.",[32],[119,120,121,122],"Anal cancer","Adaptive radiation","Chemotherapy","Radiotherapy","2026-01-30",{"date":125,"type":51},"2026-02-03",{"date":127,"type":51},"2023-05-18",{"date":129,"type":20},"2028-12-31",{"name":131,"class":82},"Columbia University",1,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":132},"100464520","a-global-record-of-patients-with-anal-squamous-cell-carcinoma-with-and-without-hiv-infection-100464520","NCT05328765","A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection","ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection","ACTION HIV","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Confirmed histological diagnosis of anal canal squamous cell carcinoma. Basaloid subtype is accepted\n* Have underundered serological test for HIV infection\n* Any clinical stage\n\nExclusion Criteria:\n\n* Lack of data on treatments and clinical outcomes",{"count":142,"type":20},300,"OBSERVATIONAL","Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity \\[IMRT\\], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.",[32,146],"HIV Infections",[146,32],"2025-03-06",{"date":150,"type":51},"2025-03-07",{"date":152,"type":51},"2023-06-09",{"date":154,"type":20},"2025-04-24",{"name":156,"class":82},"Latin American Cooperative Oncology Group",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":132},"100569724","high-resolution-anuscopy-study-100569724","NCT06697964","High Resolution Anuscopy Study","Inclusion Criteria:\n\n* All patients who have undergone HRA and all future patients referred for HRA in UZ Brussel\n* 18 years or older\n* Understands and able to speak and write in French, Dutch or English\n\nExclusion Criteria:\n\n* None",{"count":164,"type":20},500,"The majority of anal squamous cell carcinomas (SCC) stem from infection with high-risk human papillomavirus (HPV). Anal SCC is rare among the general population but affects several populations disproportionately.\n\nHigh-risk groups are screened through anal swabs for anal cytology and detection of high risk human papillomavirus (HR HPV). HRA referral is recommended for individuals with abnormal cytology.\n\nHRA represents the only method to identify precancerous lesions of the anal canal, with only few specialists knowledgeable about it.\n\nAt UZ Brussel, the investigators collected a wealth of data about HPV infection and its association with anal pathology. By establishing a comprehensive study, the investigators can delve into this data with specific research questions, conducting valuable research to provide answers to pressing clinical questions and contribute to advancements in medical understanding and treatment.",[167,32],"Human Papilloma Virus","2025-02-14",{"date":170,"type":51},"2025-02-19",{"date":172,"type":51},"2024-08-08",{"date":174,"type":20},"2029-07",{"name":176,"class":82},"Universitair Ziekenhuis Brussel",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":132},"100472972","re-optimization-based-online-adaptive-radiotherapy-of-anal-cancer-100472972","NCT05438836","Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A","Inclusion Criteria:\n\n* Biopsy-verified anal cancer\n* Eligible for curative intended radiotherapy\n* Written and oral consent\n\nExclusion Criteria:\n\n* Other malignant disease within the past 5 years (excluding basal cell carcinoma)",{"count":186,"type":20},205,"A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).",[189,190,32],"Anal Cancer","Anal Carcinoma",[192,119,193],"adaptive radiotherapy","Online Adaptive radiotherapy (oART)","2023-09-21",{"date":196,"type":51},"2023-09-25",{"date":198,"type":51},"2022-01-01",{"date":200,"type":20},"2031-01-01",{"name":202,"class":82},"Herlev Hospital"]